Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15698MR)

This product GTTS-WQ15698MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15698MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1612MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ5794MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ10246MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ10528MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ8989MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ15613MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ12070MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ6024MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW